Similar articles for PMID: 22064461

Year	Number of Results
1989	1
1991	1
1999	1
2000	1
2001	2
2002	10
2003	13
2004	18
2005	7
2006	12
2007	8
2008	8
2009	4
2010	5
2011	5
2012	2
2013	3
2014	3
2015	1
2017	1
2021	2
2024	0

1

Clinical radioimmunotherapy--the role of radiobiology.

Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. Pouget JP, et al. Nat Rev Clin Oncol. 2011 Nov 8;8(12):720-34. doi: 10.1038/nrclinonc.2011.160. Nat Rev Clin Oncol. 2011. PMID: 22064461 Review.

2

General overview of radioimmunotherapy of solid tumors.

Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. Navarro-Teulon I, et al. Immunotherapy. 2013 May;5(5):467-87. doi: 10.2217/imt.13.34. Immunotherapy. 2013. PMID: 23638743 Review.

3

Radioimmunotherapy of solid tumors: searching for the right target.

Song H, Sgouros G. Song H, et al. Curr Drug Deliv. 2011 Jan;8(1):26-44. doi: 10.2174/156720111793663651. Curr Drug Deliv. 2011. PMID: 21034423 Free PMC article. Review.

4

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).

Hernandez MC, Knox SJ. Hernandez MC, et al. Semin Oncol. 2003 Dec;30(6 Suppl 17):6-10. doi: 10.1053/j.seminoncol.2003.10.005. Semin Oncol. 2003. PMID: 14710397 Review.

5

Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.

Jacene HA, Filice R, Kasecamp W, Wahl RL. Jacene HA, et al. J Nucl Med. 2007 Nov;48(11):1767-76. doi: 10.2967/jnumed.107.043489. Epub 2007 Oct 17. J Nucl Med. 2007. PMID: 17942813 Free article.

6

Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.

Witzig TE. Witzig TE. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.

7

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

8

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.

9

[Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].

Emmanouilides C. Emmanouilides C. Rev Esp Med Nucl. 2006 Jan-Feb;25(1):42-54. doi: 10.1157/13083351. Rev Esp Med Nucl. 2006. PMID: 16540013 Review. Spanish.

10

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.

Witzig TE. Witzig TE. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. doi: 10.1007/s002800100312. Cancer Chemother Pharmacol. 2001. PMID: 11587375 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year